Core Viewpoint - Ascentage Pharma Group International is actively participating in investor conferences to enhance its visibility and engagement with investors, showcasing its innovative therapies for cancer treatment [1][8]. Company Overview - Ascentage Pharma is a global, commercial stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies to meet unmet medical needs in cancer [3]. - The company has developed a robust pipeline of innovative drug products, including inhibitors targeting key proteins in the apoptotic pathway and next-generation kinase inhibitors [3]. Key Products - The lead asset, Olverembatinib, is the first third-generation BCR-ABL1 inhibitor approved in China for treating chronic myeloid leukemia (CML) with T315I mutations and is included in the China National Reimbursement Drug List [4]. - The second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for treating various hematologic malignancies and is currently being commercialized in China [5]. Clinical Trials - Ascentage Pharma is conducting a global registrational Phase III trial, POLARIS-2, for Olverembatinib in CML, along with additional Phase III trials for newly diagnosed Ph+ acute lymphoblastic leukemia (ALL) and SDH-deficient gastrointestinal stromal tumors (GIST) [4]. - The company is also running four global registrational Phase III trials for Lisaftoclax, including studies in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and acute myeloid leukemia (AML) [5]. Partnerships and Collaborations - Ascentage Pharma has established a portfolio of global intellectual property rights and formed partnerships with leading biotechnology and pharmaceutical companies, including Takeda, AstraZeneca, Merck, and Pfizer [6].
Ascentage Pharma to Participate in Three Upcoming Investor Conferences